Episode 19: Reimagining Cancer Drug DevelopmentIn this episode, we discuss the way cancer drug development can be reimagined using AI and machine learning. Traditional drug development faces a high failure rate, highlighting the importance of understanding a drug's mechanism of action to improve success rates. AI and computational models that analyze data from various modalities, such as genomics and clinical information, can identify novel targets and enhance precision medicine. Advancements...

Microbial drug discovery holds immense promise in revolutionizing healthcare. Although fungi and other microbes have long been a source of natural compounds with therapeutic potential, advancements in technology have made the search for new candidates easier than ever. By harnessing the power of artificial intelligence and machine learning, researchers can rapidly explore the rich genetic diversity of fungi and predict therapeutic potential. This convergence of science and technology will...

Episode 17: Biomarker Identification for Early Disease DetectionWhen diseases such as cancers are detected in their early stages, before they have spread, the overall survival rate is significantly higher than when diagnosed in later stages. Developing biomarker tests that detect early-stage tumors is complex and difficult, but quite rewarding, leading to improved characterization, treatment, and management of cancer. Determining which types of data (genomic, proteomic, etc.) are most...

Episode 16: Digital Precision MedicinePrecision medicine is a multifaceted approach to designing and delivering individualized patient treatments. Using multi-omic, environmental, lifestyle, and other data, researchers aim to more accurately develop treatment and prevention strategies tailored to each unique patient. The promise of precision medicine is huge, but it also creates new challenges around data capture, storage, computation, and creation of algorithms for prediction and analysis....

Traditionally, drug targets are found by scouring scientific publications for insights into molecular pathways or known causative genetic variants, linked to disease. The failure rate of drug candidates in the clinic, even in relatively late-stage clinical trials, is quite high and is extremely costly. Fundamentally, finding better targets will lead to development of better medicines. In this episode, we discuss how artificial intelligence (AI) and the increasing availability of complex...

Digital therapeutics are software-driven, evidence-based products used to prevent, manage, or treat a medical disease or disorder. Digital therapeutics enable patients to be more aware of and play a more active role in managing their health and can improve access for patients for whom visiting a clinician is challenging. This significantly improves health outcomes and reduces healthcare demands as compared to more traditional interventions alone. Digital therapeutics are expected to grow...

Personalized medicine is critical to the future of our healthcare and wellness. Using vast sets of clinical, genomic, proteomic, and other patient data, potentially lifechanging treatments can be discovered and delivered to patients. However, implementation of personalized medicine faces unique challenges, partly because it is focused on individuals, each with their own unique genetics and history, whereas clinical trials tend to average across populations. What changes are needed for...

Synthetic biology is the design, testing, and construction of new, standardized biological parts and devices, and programming them to do something productive. Significant medical breakthroughs are already happening as a result of advances in synthetic biology. From antiviral treatment and immune cell engineering to biomonitoring, the applications of synthetic biology are endless, creating new opportunities for innovative informatics. In this episode, we discuss revolutionary applications of...

Over the past three decades, since the first monoclonal antibody was approved for clinical use in the U.S., antibody techniques and technologies have advanced radically. However, the supporting informatics have evolved at a much slower pace. There are significant informatic challenges throughout the research process, from concept to regulatory submission. How can a holistic informatics strategy support gaining clearer insights into scientific operations, make smarter decisions about their...

Data liquidity, the ability of data to flow easily and securely, provides tremendous value for biopharma researchers. Open access is paving the way for increased collaboration and discovery. However, additional initiatives are needed to further promote the management and sharing of scientific data and ensure that information is quickly available to researchers. This episode highlights the needs, solutions, and challenges of ensuring interoperability of research data throughout the data...

Increasingly, pharma is looking at partnerships and collaborations to increase the velocity of drug discovery and development. Common data sharing platforms are not built to meet lab-specific requirements. In addition to discussing the necessity of simple and secure collaboration, listeners will learn about the dangers of not using proper tools.

Capture, management, and sharing of research data and metadata are a growing concern for the biopharma industry. Learn how data standardization can facilitate collaboration and improve accessibility.

As biopharma research and development continues to transform digitally, the industry as a whole struggles with guidance on how data and relevant metadata are captured, managed, and shared. Typically experimental data are siloed,

Sequencing is used to identify novel drug targets and genetically stratifying clinical trial patients, improving the power of precision medicine. However, the global disparity of genomic technologies is increasing. How will this affect drug development, particularly for non-European ethnicities? Why is it important to have a global context for targeted therapies?

Sequencing is used to identify novel drug targets and genetically stratifying clinical trial patients, improving the power of precision medicine. However, the global disparity of genomic technologies is increasing. How will this affect drug development, particularly for non-European ethnicities? Why is it important to have a global context for targeted therapies?

Life science companies are looking to modernize their research environments and build the Lab of the Future. From early discovery to preclinical research, how can technology help automate the lab and accelerate discoveries?

Life science companies are looking to modernize their research environments and build the Lab of the Future. From early discovery to preclinical research, how can technology help automate the lab and accelerate discoveries?

What are the theories, algorithmic principles, and limitations of active learning? What are some current applications of active learning within BioPharma drug screening and optimization? How can active learning accelerate multi-dimensional drug discove...

What is the vision of interactive data exploration beyond enriching visualizations and facilitating the integration of data? Within the context of research, what are the challenges and opportunities in building next-generation visual analytics? Listen to find out.

What is the vision of interactive data exploration beyond enriching visualizations and facilitating the integration of data? Within the context of research, what are the challenges and opportunities in building next-generation visual analytics?

Artificial Intelligence (AI) and Machine Learning (ML) are big topics getting lots of attention within BioPharma. What is the role of AI/ML in genomics? How can we separate the hype of AI/ML from reality? Listen in to find out this and more.

Artificial Intelligence (AI) and Machine Learning (ML) are big topics getting lots of attention within BioPharma. What is the role of AI/ML in genomics? How can we separate the hype of AI/ML from reality? Listen in to find out this and more.